Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 21, 2020
Reporting Period: Specific event date of September 21, 2020.
Key Financial Metrics
This filing reports a specific capital transaction rather than periodic financial performance. Consequently, revenue, profit, cash flow, margins, and debt levels are not disclosed in this document.
- Capital Raised: $500,000.20
- Shares Issued: 357,143 restricted shares of common stock
- Implied Price Per Share: Approximately $1.40
- Investor: Bespoke Growth Partners, Inc.
Material Changes
The filing discloses an unregistered sale of equity securities. On September 21, 2020, the Company entered into a securities purchase agreement to sell 357,143 restricted shares to Bespoke Growth Partners, Inc. for an aggregate purchase price of $500,000.20. The transaction was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Outlook, Risks, and Unusual Items
Management Commentary: The filing notes that Bespoke's principal is Mark H. Peikin, who serves as Adial's Chief Strategy Officer. The shares were acquired for investment purposes only and not for resale.
Risks and Contingencies: The Shares are restricted and have not been registered under the Securities Act. They may not be offered or sold in the United States absent registration or an applicable exemption. The filing explicitly states it is not an offer to sell or a solicitation of an offer to buy the Shares.
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the relationship and potential conflicts of interest regarding Mark H. Peikin (Chief Strategy Officer) as the principal of the investor.
- Review the Company's most recent 10-Q or 10-K for current cash position and liquidity status, as this 8-K does not provide balance sheet data.
- Check for any subsequent filings regarding the registration rights or resale restrictions of the 357,143 shares issued.